AUTHORS
David M. Mueller, MD, Sharon Santhosh, MD2, Adit Singhal, MD, MS3, David W Chitty, MD4, Kelli Cole5, Ruthee Bayer, MD6, Jaime Andres Suarez-londono, MD7, Douglas E Gladstone, MD8, Stephanie Boisclair, MD9
AFFILIATIONS
1 Northwell Health, New Hyde Park, New York, United States
2 Northwell Health, New Hyde Park, New York, United States
3 Northwell Health, New Hyde Park, New York, United States
4 Northwell Health, New Hyde Park, New York, United States
5 Northwell Health, New Hyde Park, New York, United States
6 Northwell Health, New Hyde Park, New York, United States
7 Northwell Health, New Hyde Park, New York, United States
8 Northwell Health, New Hyde Park, New York, United States
9 Northwell Health, New Hyde Park, New York, United States
ABSTRACT
Background:
The role for allogeneic transplantation (allo-HSCT) in the management of TP53-mutated AML remains unclear. Without transplant, outcomes are dismal. TP53-mutated AML can be categorized as single-hit (SH) or double-hit (DH) as an approximation for allelic status. The impact of TP53 allelic status on transplant outcomes is not well defined. We evaluated allo-HSCT utilization and outcomes across TP53 allelic subgroups.
Methods:
Cases of TP53-mutated AML diagnosed 1/2019 to 7/2025 were analyzed. TP53-mutated AML, defined by a TP53 mutation (VAF ≥2%), 17p cytogenetic abnormality, or both, was classified per Grob et al., 2022. DH was defined as ≥2 TP53 mutations, a TP53 mutation with 17p abnormality, or a single mutation with VAF >55%. To reduce immortal-time bias inherent to transplant timing, comparisons of transplanted versus non-transplanted patients were restricted to those who achieved a morphologic leukemia-free state (MLFS) and remained alive ≥4 months, the median time to transplant. Post-transplant outcomes were analyzed from day 0, whereas survival comparisons were measured from first MLFS. Overall survival (OS) and relapse-free survival (RFS) were estimated by Kaplan–Meier methods. Estimated cumulative incidences (ECI) were calculated using competing-risks methods with Gray’s test.
Results:
A total of 113 TP53-mutated AML patients were identified (median age 71.3 years); 26.5% were SH, 61.9% were DH, and 11.5% were unclassifiable. Most had de novo AML (56.6%) and received HMA±venetoclax induction (63.7%). Of classifiable patients, 53 achieved MLFS and 23 underwent allo-HSCT in first remission. Of those that underwent allo-HSCT (of any hit status), median OS, RFS, and GVHD- and relapse-free survival (GRFS) from transplant were 12.4 mo (6.16–NR), 12 mo (3.4–NR), and 8.3 mo (4–21.4), respectively.The 1-year ECI of grade II–IV acute GVHD was 27.1% with no grade III–IV events; the 2-year ECI of moderate/severe chronic GVHD was 9.1%. Patients who developed GVHD of any grade (n=9) had improved 2-year OS (76.2% vs 25.4%; p=0.006) and RFS (76.2% vs 23.4%; p=0.004). One-year ECI of relapse and NRM were 27% and 8.7%. There was no difference in OS, RFS, or GRFS by conditioning intensity, donor source, or GVHD prophylaxis regimen. In the MLFS-eligible cohort, allo-HSCT was associated with significantly improved OS (17.7 vs 10.0 mo; p=0.0045) and RFS (19.2 vs 9.2 mo; p=0.0005) compared with non-transplanted patients. This benefit was present in both SH and DH groups: each demonstrated improved OS and RFS with allo-HSCT. Within the allo-HSCT cohort, SH patients had longer OS (81.2 vs 12.3 mo) and RFS (81.2 vs 8.3 mo) than DH patients, though differences were not statistically significant (OS p=0.29; RFS p=0.43). SH and DH groups were similar in ECIs of relapse, NRM, and incidence of acute or chronic GVHD. Three DH patients with Day +60 MRD positivity received HMA maintenance.
Conclusion:
Allo-HSCT was associated with a significant OS and RFS advantage in TP53-mutated AML patients who achieved MLFS and remained transplant-eligible. This benefit was observed in both SH and DH disease. These findings support offering allo-HSCT to appropriately selected TP53-mutated AML patients who achieve MLFS, irrespective of hit status, and highlight the need for validation in larger prospective cohorts.
DISCLOSURES
David M. Mueller, MD: No relevant conflicts of interest to declare.